Annual EBITDA
-$18.83 M
-$3.58 M-23.45%
31 December 2023
Summary:
CNS Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization is currently -$18.83 million, with the most recent change of -$3.58 million (-23.45%) on 31 December 2023. During the last 3 years, it has fallen by -$9.39 million (-99.43%). CNSP annual EBITDA is now -391.60% below its all-time high of -$3.83 million, reached on 31 December 2019.CNSP EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$5.60 M
-$3.08 M-121.85%
30 September 2024
Summary:
CNS Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization is currently -$5.60 million, with the most recent change of -$3.08 million (-121.85%) on 30 September 2024. Over the past year, it has dropped by -$1.08 million (-23.96%). CNSP quarterly EBITDA is now -3197.76% below its all-time high of -$169.90 thousand, reached on 30 September 2018.CNSP Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$17.04 M
-$1.08 M-6.79%
30 September 2024
Summary:
CNS Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization is currently -$17.04 million, with the most recent change of -$1.08 million (-6.79%) on 30 September 2024. Over the past year, it has increased by +$1.56 million (+8.37%). CNSP TTM EBITDA is now -6684.99% below its all-time high of -$251.10 thousand, reached on 30 June 2018.CNSP TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CNSP EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -23.4% | -24.0% | +8.4% |
| 3 y3 years | -99.4% | -47.1% | -19.8% |
| 5 y5 years | -156.4% | -702.3% | -115.0% |
CNSP EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -99.4% | at low | -121.8% | at low | -27.4% | +9.5% |
| 5 y | 5 years | -391.6% | at low | -702.3% | at low | -344.7% | +9.5% |
| alltime | all time | -391.6% | at low | -3197.8% | +15.3% | -6685.0% | +9.5% |
CNS Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$5.60 M(+121.9%) | -$17.04 M(+6.8%) |
| June 2024 | - | -$2.53 M(-28.6%) | -$15.95 M(-8.5%) |
| Mar 2024 | - | -$3.54 M(-34.1%) | -$17.45 M(-7.4%) |
| Dec 2023 | -$18.83 M(+23.5%) | -$5.37 M(+18.8%) | -$18.83 M(+1.3%) |
| Sept 2023 | - | -$4.52 M(+12.5%) | -$18.59 M(+6.3%) |
| June 2023 | - | -$4.02 M(-18.4%) | -$17.49 M(+2.7%) |
| Mar 2023 | - | -$4.93 M(-4.0%) | -$17.03 M(+11.7%) |
| Dec 2022 | -$15.26 M(+5.4%) | -$5.13 M(+50.2%) | -$15.26 M(+14.1%) |
| Sept 2022 | - | -$3.42 M(-4.1%) | -$13.37 M(-2.9%) |
| June 2022 | - | -$3.56 M(+13.2%) | -$13.76 M(-1.8%) |
| Mar 2022 | - | -$3.15 M(-3.1%) | -$14.01 M(-3.2%) |
| Dec 2021 | -$14.47 M | -$3.25 M(-14.8%) | -$14.47 M(+1.8%) |
| Sept 2021 | - | -$3.81 M(+0.0%) | -$14.22 M(+14.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2021 | - | -$3.81 M(+5.6%) | -$12.42 M(+12.1%) |
| Mar 2021 | - | -$3.61 M(+20.3%) | -$11.08 M(+17.4%) |
| Dec 2020 | -$9.44 M(+146.5%) | -$3.00 M(+49.3%) | -$9.44 M(+5.3%) |
| Sept 2020 | - | -$2.01 M(-18.7%) | -$8.97 M(+17.1%) |
| June 2020 | - | -$2.47 M(+25.7%) | -$7.66 M(+36.7%) |
| Mar 2020 | - | -$1.97 M(-22.1%) | -$5.60 M(+46.2%) |
| Dec 2019 | -$3.83 M(-47.8%) | -$2.52 M(+261.2%) | -$3.83 M(-51.7%) |
| Sept 2019 | - | -$698.40 K(+68.3%) | -$7.93 M(+7.1%) |
| June 2019 | - | -$414.90 K(+112.7%) | -$7.40 M(+2.3%) |
| Mar 2019 | - | -$195.10 K(-97.1%) | -$7.23 M(+2.8%) |
| Dec 2018 | -$7.35 M | -$6.62 M(+3794.9%) | -$7.04 M(+1571.9%) |
| Sept 2018 | - | -$169.90 K(-32.3%) | -$421.00 K(+67.7%) |
| June 2018 | - | -$251.10 K | -$251.10 K |
FAQ
- What is CNS Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for CNS Pharmaceuticals?
- What is CNS Pharmaceuticals annual EBITDA year-on-year change?
- What is CNS Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for CNS Pharmaceuticals?
- What is CNS Pharmaceuticals quarterly EBITDA year-on-year change?
- What is CNS Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for CNS Pharmaceuticals?
- What is CNS Pharmaceuticals TTM EBITDA year-on-year change?
What is CNS Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of CNSP is -$18.83 M
What is the all time high annual EBITDA for CNS Pharmaceuticals?
CNS Pharmaceuticals all-time high annual earnings before interest, taxes, depreciation & amortization is -$3.83 M
What is CNS Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, CNSP annual earnings before interest, taxes, depreciation & amortization has changed by -$3.58 M (-23.45%)
What is CNS Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of CNSP is -$5.60 M
What is the all time high quarterly EBITDA for CNS Pharmaceuticals?
CNS Pharmaceuticals all-time high quarterly earnings before interest, taxes, depreciation & amortization is -$169.90 K
What is CNS Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, CNSP quarterly earnings before interest, taxes, depreciation & amortization has changed by -$1.08 M (-23.96%)
What is CNS Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of CNSP is -$17.04 M
What is the all time high TTM EBITDA for CNS Pharmaceuticals?
CNS Pharmaceuticals all-time high TTM earnings before interest, taxes, depreciation & amortization is -$251.10 K
What is CNS Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, CNSP TTM earnings before interest, taxes, depreciation & amortization has changed by +$1.56 M (+8.37%)